| Title: | Implementation and external validation of the Cambridge Multimorbidity Score in the UK Biobank cohort |
| Journal: | BMC Medical Research Methodology |
| Published: | 20 Mar 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38509467/ |
| DOI: | https://doi.org/10.1186/s12874-024-02175-9 |
| URL: | https://bmcmedresmethodol.biomedcentral.com/counter/pdf/10.1186/s12874-024-02175-9 |
Publication 10088
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundPatients with multiple conditions present a growing challenge for healthcare provision. Measures of multimorbidity may support clinical management, healthcare resource allocation and accounting for the health of participants in purpose-designed cohorts. The recently developed Cambridge Multimorbidity scores (CMS) have the potential to achieve these aims using primary care records, however, they have not yet been validated outside of their development cohort.MethodsThe CMS, developed in the Clinical Research Practice Dataset (CPRD), were validated in UK Biobank participants whose data is not available in CPRD (the cohort used for CMS development) with available primary care records (n = 111,898). This required mapping of the 37 pre-existing conditions used in the CMS to the coding frameworks used by UK Biobank data providers. We used calibration plots and measures of discrimination to validate the CMS for two of the three outcomes used in the development study (death and primary care consultation rate) and explored variation by age and sex. We also examined the predictive ability of the CMS for the outcome of cancer diagnosis. The results were compared to an unweighted count score of the 37 pre-existing conditions.ResultsFor all three outcomes considered, the CMS were poorly calibrated in UK Biobank. We observed a similar discriminative ability for the outcome of primary care consultation rate to that reported in the development study (C-index: 0.67 (95%CI:0.66-0.68) for both, 5-year follow-up); however, we report lower discrimination for the outcome of death than the development study (0.69 (0.68-0.70) and 0.89 (0.88-0.90) respectively). Discrimination for cancer diagnosis was adequate (0.64 (0.63-0.65)). The CMS performs favourably to the unweighted count score for death, but not for the outcomes of primary care consultation rate or cancer diagnosis.ConclusionsIn the UK Biobank, CMS discriminates reasonably for the outcomes of death, primary care consultation rate and cancer diagnosis and may be a valuable resource for clinicians, public health professionals and data scientists. However, recalibration will be required to make accurate predictions when cohort composition and risk levels differ substantially from the development cohort. The generated resources (including codelists for the conditions and code for CMS implementation in UK Biobank) are available online.</p>
9 Authors
- Hannah Harrison
- Samantha Ip
- Cristina Renzi
- Yangfan Li
- Matthew Barclay
- Juliet Usher-Smith
- Georgios Lyratzopoulos
- Angela Wood
- Antonis C. Antoniou
Enabling scientific discoveries that improve human health